US2017281585A1PendingUtilityA1
Methods for the treatment of sialorrhea
Est. expiryNov 13, 2032(~6.3 yrs left)· nominal 20-yr term from priority
Inventors:Dinesh C. Patel
A61K 9/2054A61K 9/2018A61K 31/216A61K 9/7061A61K 9/2009A61K 9/0056
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides safe and effective methods for the treatment of sialorrhea (excessive drooling) by administering an effective amount of N-desethyloxybutynin, or an optical R- or S-isomer thereof or a pharmaceutically acceptable salt thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating sialorrhea in a subject comprising:
providing a therapeutically effective amount of a N-desethyloxybutynin compound; and non-parenterally administering the therapeutically effective amount of the N-desethyloxybutynin compound to the subject.
2 . The method of claim 1 , wherein the N-desethyloxybutynin comprises (R)-N-desethyloxybutynin or a pharmaceutically acceptable salt thereof or (S)-N-desethyloxybutynin or a pharmaceutically acceptable salt thereof, or a combination thereof.
3 . The method of claim 1 , wherein the N-desethyloxybutynin is administered via oral, buccal, transdermal, inhalation, implantation, vaginal or rectal route of administration.
4 . The method of claim 1 , wherein the N-desethyloxybutynin is orally administered.
5 . The method of claim 4 , wherein the oral administration is administered either transmucosally through the oral cavity or enterally, or by a combination thereof.
6 . The method of claim 1 , wherein the N-desethyloxybutynin is administered as an immediate release dosage form.
7 . The method of claim 1 , wherein the N-desethyloxybutynin is administered as a controlled release dosage form.
8 . The method of claim 1 , wherein the amount of N-desethyloxybutynin is from about 1 mg to about 100 mg.
9 . The method of claim 8 , where in the amount is from about 2 mg to about 30 mg of N-desethyloxybutynin.
10 . The method of claim 1 , wherein the N-desethyloxybutynin is administered as an oral tablet, capsule, or liquid.Join the waitlist — get patent alerts
Track US2017281585A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.